Q-omics provides the consensus-scored C2orf42 profile across patient tissues and cancer cell-line models. C2orf42 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C2orf42 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, C2orf42 protein abundance shows 23,932 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, and HNSC as cancer lineages where C2orf42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf42 survival associations across molecular data types. C2orf42 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf42 RNA expression–survival associations across cancer types. High C2orf42 expression shows unfavorable associations in ACC, STAD and MESO, but favorable associations in KIRC, LUSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C2orf42 RNA expression.
This table summarizes C2orf42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C2orf42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf42 shows lower tumor expression in KICH, THCA, UCEC and KIRC and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher C2orf42 RNA expression in tumor versus normal tissue (log2 FC = +0.518, t-test p < 0.001).
This table shows molecular features associated with C2orf42 in patient tissues and cancer cell lines. In patient samples, C2orf42 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
